A Link Between Air Pollution and Dementia Risk Is Supplied by New Data.

Published Date: 23 Apr 2023

According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.

Read Full News

Latest News

COPD in 2025: Year in Review

COPD in 2025: Year in Review

Characterizing COPD - Lung Cancer Patients, with Joseph Friedberg, MD Joseph Friedberg, MD, Kevin Kunzmann

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Todays Updates

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Hormonal Disorders in 2025: Year in Review

Hormonal Disorders in 2025: Year in Review

Todays Updates

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Hormonal Disorders in 2025: Year in Review

Hormonal Disorders in 2025: Year in Review

Latest News

COPD in 2025: Year in Review

Friedberg discusses the inconsistent clinical pathways from disease progression to intervention in patients with a pair of highly deadly lung diseases.

Post-NICU PM2.5 Exposure Raises Asthma Risk in Children With Bronchopulmonary Dysplasia

Asthma Biologic Adherence Shaped by Psychological, Clinical, Systemic Factors

FDA Approves Nerandomilast (Jascayd) Tablets for Progressive Pulmonary Fibrosis

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

News All Time

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

Tezepelumab Drastically Reduces OCS Use for Asthma in Open-Label Trial

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

FDA Approval Adds Tezepelumab to CRSwNP Treatment Landscape Victoria Johnson

Tezepelumab is the first TSLP-targeting biologic to be approved for chronic rhinosinusitis with nasal poylps.

Sleep Apnea Significantly Impacts Mortality Benefit of GLP-1s Kevin Kunzmann

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

4 Trials That May Change Pulmonary Embolism, with Parth Rali, MD Parth Rali, MD

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Redefining Severe Airway Disease Care: Clinicians Weigh In on Biologics and Barriers Victoria Johnson

Experts explore the evolution of asthma and COPD treatments with targeted biologic therapies.

The Case for More Spirometry, Pulmonary Function Testing, with Meredith McCormack, MD Kevin Kunzmann

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

Dupilumab, Tezepelumab Provide Consistent Real-World Severe Asthma Outcomes Kevin Kunzmann

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.

Opportunities to Define and Treat Indoor Air Quality, with Sarath Raju, MD, MPH Sarath Raju, MD, MPH

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

What Ails Lung Cancer Screening, with Douglas Wood, MD Douglas Wood, MD

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

Recommended News For You

No Benefit for PD-1 Inhibitors in Certain Gastroesophageal Cancers, FDA Panel Says

Early cancer detection during pregnancy and the postpartum period may be aided by breast milk examination.

Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer

Mental health risk persists years after cancer diagnosis

A small rise in cancer was observed following the 1986 Chernobyl accident.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

New tumor therapy approach reduces costs and side effects while increasing accessibility

Recommended Articles For You

Mechanisms, Efficacy, and Survival Outcomes in AML, Squamous Cell Carcinoma, & Non-Hodgkin Lymphoma 

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment 

Integrative Cancer Care: Nutrition, Social Work, Care Coordination, and Genetic Counseling 

The Next Generation of Precision: How Multi-Specific Antibodies are Redefining Oncology's Future - A 2025 Review 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Obesity linked to subsequent neoplasms in childhood cancer survivors

2.

Investigations may result in novel combination therapies for early-stage lung cancers.

3.

A new theranostic drug targets different cancer types.

4.

High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment

5.

After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.

1.

Early Detection of Breast Cancer: Signs, Symptoms, and Screening Methods

2.

Radiation in Oncology: Advances, Applications, and Accessibility

3.

7 Subtle Signs of Leukemia: How to Spot the Symptoms Early

4.

Cancer Staging: Updates, Clinical Insights, and Educational Resources for Medical Professionals

5.

Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.

2.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

3.

Thromboprophylaxis In Medical Settings- An Update

4.

Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL

5.

Should We Use DARA Up Front As First-Line Therapy in MM?


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot